Abeona Therapeutics Inc Expected to Post Q1 2018 Earnings of ($0.21) Per Share (ABEO)
Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Abeona Therapeutics in a report issued on Monday. Jefferies Group analyst M. Raycroft forecasts that the biopharmaceutical company will post earnings of ($0.21) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $28.00 target price on the stock. Jefferies Group also issued estimates for Abeona Therapeutics’ Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.90) EPS, FY2019 earnings at ($0.41) EPS, FY2020 earnings at $0.33 EPS and FY2021 earnings at $1.67 EPS.
A number of other equities research analysts have also recently commented on ABEO. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, November 22nd. ValuEngine cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada restated a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Abeona Therapeutics presently has an average rating of “Buy” and a consensus target price of $27.33.
Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.24 million. Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The company’s revenue was down 16.0% on a year-over-year basis.
Several hedge funds have recently bought and sold shares of the company. Viking Global Investors LP boosted its holdings in shares of Abeona Therapeutics by 80.5% during the fourth quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock worth $64,046,000 after purchasing an additional 1,802,007 shares during the last quarter. BlackRock Inc. raised its position in shares of Abeona Therapeutics by 15.1% in the 4th quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after buying an additional 245,217 shares during the period. Vanguard Group Inc. raised its position in shares of Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after buying an additional 108,730 shares during the period. State Street Corp purchased a new position in shares of Abeona Therapeutics in the 2nd quarter worth $1,900,000. Finally, Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 11.4% in the 4th quarter. Geode Capital Management LLC now owns 277,958 shares of the biopharmaceutical company’s stock worth $4,405,000 after buying an additional 28,498 shares during the period. Institutional investors and hedge funds own 62.64% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.